Plantar fibromatosis is a progressive condition with no FDA-approved nonsurgical treatment options. With no official treatment guidelines available, Keenova and its clinical partners are working to ...
Clinical Trials Arena on MSN
Keenova seeks Xiaflex expansion on late-stage rare disease win
If approved, Xiaflex would become the first FDA-approved therapy to reach patients with plantar fibromatosis.
Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium histolyticum) for the treatment of plantar fibromatosis, a chronic ...
Keenova Therapeutics plc, a leading US-focused branded therapeutics company, announced positive results from its phase 3 clinical trial of Xiaflex (collagenase clostridium histolyticum) for the ...
Previously unpublished clinical data support the potential long‑term safety and efficacy of collagenase clostridium histolyticum (CCH) for plantar fibromatosis. The findings will be presented at the ...
Treatment with CCH led to a clinically meaningful and statistically significant reduction in daily foot pain at week 12 compared with placebo. Topline data were announced from a phase 3 trial ...
DUBLIN, Sept. 21, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that data from clinical studies of collagenase clostridium histolyticum (CCH) in patients with plantar ...
MALVERN, Pa., July 24, 2025 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today that three presentations related to plantar fibromatosis (PFI) and plantar fasciitis (PFA) will be shared during ...
Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX® (collagenase clostridium ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results